Synapse - Works

Results (5712)

CheckMate 436: Primary efficacy and safety analysis of the phase 2 study evaluating nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Meeting Abstract

Santoro, A.; Moskowitz, A.; Ferrari, S.; Carlo-Stella, C.; Collins, G.; Fanale, M.; Francis, S.; Sacchi, M.; Savage, K.
British Journal of Haematology (2021)

Fulltext@MSK | Save

Fludarabine-exposure predicts disease control following CD19-specific CAR T cell (tisagenlecleucel); A report from pediatric real-world CAR Consortium

Meeting Abstract

Curran, K. J.; Fabrizio, V. A.; Mauguen, A.; Boelens, J. J.; Baggott, C.; Prabhu, S.; Placenta, H.; Phillips, C. L.; Rossoff, J.; Stefanski, H.; more...
Cytotherapy (2021)

Fulltext@MSK | Save

Why drug and radiation combination synergism or antagonism can be quantitatively determined with the mass-action law based pharmacodynamics equation, algorithm and computer simulation

Meeting Abstract

Chou, T. C.
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Radiation therapy enhances the presentation of phosphopeptides by MHC-I on cancer cells

Meeting Abstract

Van Nest, S. J.; Yaron, T. M.; Klatt, M. G.; Dephoure, N. E.; Getz, G.; Santambrogio, L.; Elemento, O.; Scheinberg, D.; Demaria, S.; Cantley, L. C.
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study

Meeting Abstract

Eyre, T.; Shah, N. N.; Alencar, A.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; more...
British Journal of Haematology (2021)

Fulltext@MSK | Save

Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490)

Meeting Abstract

Radford, J.; Dlugosz-Danecka, M.; Connors, J. M.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; more...
British Journal of Haematology (2021)

Fulltext@MSK | Save

CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: Update of manifest phase 2 study

Meeting Abstract

Mead, A.; Mascarenhas, J.; Talpaz, M.; Patriarca, A.; Devos, T.; Palandri, F.; Passamonti, F.; Rampal, R.; Kremyanskaya, M.; Scandura, J.; more...
British Journal of Haematology (2021)

Fulltext@MSK | Save

CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as "add-on" to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: Update of MANIFEST phase 2 study

Meeting Abstract

Somervaille, T.; Verstovsek, S.; Mascarenhas, J.; Kremyanskaya, M.; Hoffman, R.; Rampal, R.; Gupta, V.; Talpaz, M.; Granacher, N.; Leber, B.; more...
British Journal of Haematology (2021)

Fulltext@MSK | Save

ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results

Meeting Abstract

Illidge, T.; Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
British Journal of Haematology (2021)

Fulltext@MSK | Save

CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/intolerant to JAK inhibitor: Update from phase 2 MANIFEST study

Meeting Abstract

Drummond, M.; Talpaz, M.; Rampal, R.; Verstovsek, S.; Kiladjian, J. J.; Vannucchi, A.; Kremyanskaya, M.; Schiller, G.; Patriarca, A.; Van Gorkom, G.; more...
British Journal of Haematology (2021)

Fulltext@MSK | Save